1.58
0.00 (0.00%)
| Penutupan Terdahulu | 1.58 |
| Buka | 1.59 |
| Jumlah Dagangan | 278,774 |
| Purata Dagangan (3B) | 532,711 |
| Modal Pasaran | 34,553,800 |
| Harga / Jualan (P/S) | 14.87 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| Margin Operasi (TTM) | -6,011.31% |
| EPS Cair (TTM) | -11.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -71.10% |
| Nisbah Semasa (MRQ) | 1.48 |
| Aliran Tunai Operasi (OCF TTM) | -66.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.95 M |
| Pulangan Atas Aset (ROA TTM) | -52.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BioXcel Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.13 |
|
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.65% |
| % Dimiliki oleh Institusi | 11.02% |
| Julat 52 Minggu | ||
| Median | 6.00 (279.75%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Mar 2026 | 6.00 (279.75%) | Beli | 1.61 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MEHTA VIMAL | - | - | 0 | 0 |
| RODRIGUEZ JAVIER | - | - | 0 | 0 |
| STEINHART RICHARD I | - | - | 0 | 0 |
| YOCCA FRANK | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| YOCCA FRANK | Pegawai | 15 Mar 2026 | Pelaksanaan pilihan | 35 | - | - |
| RODRIGUEZ JAVIER | Pegawai | 15 Mar 2026 | Pelaksanaan pilihan | 35 | - | - |
| STEINHART RICHARD I | Pegawai | 15 Mar 2026 | Pelaksanaan pilihan | 35 | - | - |
| MEHTA VIMAL | Pegawai | 15 Mar 2026 | Pelaksanaan pilihan | 219 | - | - |
| YOCCA FRANK | Pegawai | 14 Mar 2026 | Pelaksanaan pilihan | 33 | - | - |
| RODRIGUEZ JAVIER | Pegawai | 14 Mar 2026 | Pelaksanaan pilihan | 33 | - | - |
| STEINHART RICHARD I | Pegawai | 14 Mar 2026 | Pelaksanaan pilihan | 33 | - | - |
| MEHTA VIMAL | Pegawai | 14 Mar 2026 | Pelaksanaan pilihan | 164 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting |
| 12 Jan 2026 | Pengumuman | BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting |
| 07 Jan 2026 | Pengumuman | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |